XCUR Exicure, Inc.
Legal ·
Exicure's securities class action and its shareholder derivative suits are over, according to a quarterly report filed August 14, 2026. The class action settled for $5.625 million, funded by insurers, and the derivative suits were dismissed in June 2026 after court approval.
Exicure says it needs more time to finish its quarterly report and expects a net loss of approximately $1,827,911 for the quarter. Cash fell to about $2,504,054 by March 31, 2026, and its 10-K already carried a going-concern warning.
Exicure said it met Listing Rule 5250(c)(1) as of July 1, 2025, after filing its Form 10-Q for the quarter ended March 31, 2025.
Exicure told the SEC on May 15, 2025 that it cannot file its quarterly report for the period ended March 31, 2025 on time, because it has not finished the accounting for its acquisition of GPCR Therapeutics USA, Inc. The company expects to file within the five-day extension that Rule 12b-25 allows, and it says the acquisition will make the quarter's results hard to compare with last year.
The company said it needs more time on the purchase price allocation for GPCR Therapeutics USA, Inc. It expects results to change significantly from the March 31, 2024 quarter.
The bonds of KC Creation Co., Ltd. mature on April 30, 2028 and yield 2.9% a year. KC Creation expects to use the money to buy stocks of other corporations.
Exicure, Inc. was historically an early-stage biotechnology company developing nucleic acid therapies built on its spherical nucleic acid technology. After a September 2022 restructuring it suspended preclinical activities, and in September 2024 it sold its historical biotechnology intellectual property and other assets to Flashpoint Therapeutics. The company says it no longer owns any intellectual property and that its current focus is exploring transactions with potential partners that see opportunity in joining an existing, publicly-traded organization, which may be focused in Asia. In January 2025 it acquired GPCR Therapeutics USA from GPCR Therapeutics Inc under a License and Collaboration Agreement. GPCR USA completed a Phase 2 trial in January 2026 in blood cancer patients, and a current trial combines GPC-100, a small molecule antagonist of a chemokine receptor, with propranolol to mobilize stem cells in multiple myeloma patients. The company reports no current source of revenue. Its largest stockholder, Exicure HiTron Inc., beneficially owned 25% of outstanding shares as of March 17, 2026.
| Product or program | What it is | Stage |
|---|---|---|
| GPC-100 with propranolol | Chemokine receptor antagonist with propranolol for stem cell mobilization in multiple myeloma | Current clinical trial |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $500,000 |
| Research and development | $3.3 million | $0 |
| Net income (loss) | -$4.9 million | -$9.7 million |
| Cash from operations | -$8.6 million | -$2.9 million |
| Cash and equivalents | $3.7 million | $12.5 million |
Our latest story on this, dated Aug 14, 2026: "Exicure's class action and derivative suits end with court-approved settlements". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 15, 2026: "Exicure files NT 10-Q late filing notice, expects $1,827,911 first quarter net loss". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 6, 2025: "Exicure buys about $3.125 million of convertible bonds from South Korean subsidiary". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 15, 2025: "Exicure files NT 10-Q late-filing notice, needs more time on March 31, 2025 quarterly report". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "Exicure's class action and derivative suits end with court-approved settlements". The story links the filing or release it is based on. Read the story.
Exicure, Inc. trades under the ticker XCUR on NASDAQ.
Exicure, Inc. is listed on NASDAQ. Our directory also records these other listings: LSX:A40L5C.
The SEC Central Index Key (CIK) for Exicure, Inc. is 1698530. Its filings are on SEC EDGAR.
6,545,995 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Exicure, Inc. under United States.
Our directory classifies Exicure, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Exicure, Inc. is US30205M3097.
aibio.space lists Exicure, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Exicure, Inc. was historically an early-stage biotechnology company developing nucleic acid therapies built on its spherical nucleic acid technology. After a September 2022 restructuring it suspended preclinical activities, and in September 2024 it sold its historical biotechnology intellectual property and other assets to Flashpoint Therapeutics.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a financing. SEC Form 8-K (Items 1.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio